FR2492260A1 - Composition pharmaceutique pour l'administration orale contenant le facteur de coagulation viii - Google Patents
Composition pharmaceutique pour l'administration orale contenant le facteur de coagulation viii Download PDFInfo
- Publication number
- FR2492260A1 FR2492260A1 FR8119522A FR8119522A FR2492260A1 FR 2492260 A1 FR2492260 A1 FR 2492260A1 FR 8119522 A FR8119522 A FR 8119522A FR 8119522 A FR8119522 A FR 8119522A FR 2492260 A1 FR2492260 A1 FR 2492260A1
- Authority
- FR
- France
- Prior art keywords
- factor viii
- coagulation factor
- liposomes
- pharmaceutical composition
- capsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010054218 Factor VIII Proteins 0.000 title claims abstract description 60
- 102000001690 Factor VIII Human genes 0.000 title claims abstract description 60
- 229940105778 coagulation factor viii Drugs 0.000 title claims abstract description 45
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 239000002502 liposome Substances 0.000 claims abstract description 66
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims abstract description 13
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 13
- 108010039627 Aprotinin Proteins 0.000 claims abstract description 12
- 229960004405 aprotinin Drugs 0.000 claims abstract description 12
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims description 43
- 239000000463 material Substances 0.000 claims description 12
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 9
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract description 5
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract description 5
- 239000003114 blood coagulation factor Substances 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 4
- 238000011321 prophylaxis Methods 0.000 abstract description 4
- 208000031220 Hemophilia Diseases 0.000 abstract description 3
- 230000037361 pathway Effects 0.000 abstract 2
- 230000002496 gastric effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 21
- 229960000301 factor viii Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 description 13
- 239000000725 suspension Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 9
- 229940067606 lecithin Drugs 0.000 description 9
- 235000010445 lecithin Nutrition 0.000 description 9
- 239000000787 lecithin Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 7
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 6
- 102100026735 Coagulation factor VIII Human genes 0.000 description 5
- 201000003542 Factor VIII deficiency Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- -1 dimethylcarbamoylmethyl phenylacetate Chemical compound 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP55144508A JPS5770814A (en) | 1980-10-17 | 1980-10-17 | Oral preparation of blood clotting eighth factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2492260A1 true FR2492260A1 (fr) | 1982-04-23 |
| FR2492260B1 FR2492260B1 (enrdf_load_stackoverflow) | 1984-07-27 |
Family
ID=15363986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8119522A Granted FR2492260A1 (fr) | 1980-10-17 | 1981-10-16 | Composition pharmaceutique pour l'administration orale contenant le facteur de coagulation viii |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS5770814A (enrdf_load_stackoverflow) |
| DE (1) | DE3141223A1 (enrdf_load_stackoverflow) |
| ES (1) | ES506320A0 (enrdf_load_stackoverflow) |
| FR (1) | FR2492260A1 (enrdf_load_stackoverflow) |
| GB (1) | GB2085729B (enrdf_load_stackoverflow) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4536392A (en) * | 1983-06-27 | 1985-08-20 | Queen's University At Kingston | Method for controlling hemophilia in mammals |
| IT1164363B (it) * | 1983-08-03 | 1987-04-08 | Foscama Biomed Chim Farma | Procedimento terapeutico facente uso di liposomi imcorporati fruttosio 1,6 difosfato e procedimento per la preparazione degli stessi |
| JPS6150912A (ja) * | 1984-08-16 | 1986-03-13 | Shionogi & Co Ltd | リポソ−ム製剤の製造法 |
| FR2581543B1 (fr) * | 1985-05-09 | 1989-07-07 | Tressens Dominique | Pharmacotechnie permettant la realisation d'une preparation insulinique active par voie orale |
| DE3625090A1 (de) * | 1986-07-24 | 1988-01-28 | Behringwerke Ag | Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung |
| GB8822857D0 (en) * | 1988-09-29 | 1988-11-02 | Patralan Ltd | Pharmaceutical formulations |
| GB9007052D0 (en) * | 1990-03-29 | 1990-05-30 | Skua Investments Ltd | Pharmaceutical formulations |
| DE4115453A1 (de) * | 1991-05-11 | 1992-11-12 | Knoll Ag | Neue wirkstoffkombination |
| WO1994028876A1 (en) * | 1993-06-07 | 1994-12-22 | Advanced Therapies, Inc. | Liposome powders |
| FR2706302B1 (fr) * | 1993-06-18 | 1995-08-18 | Franche Comte Universite | Produit alcalinisant sous forme gastro-résistante. |
| DE4416180C2 (de) * | 1994-05-06 | 1997-08-14 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats |
| US6017891A (en) * | 1994-05-06 | 2000-01-25 | Baxter Aktiengesellschaft | Stable preparation for the treatment of blood coagulation disorders |
| DE4416166C2 (de) * | 1994-05-06 | 1997-11-20 | Immuno Ag | Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen |
| CH689139A5 (de) * | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| WO1999011242A1 (en) * | 1997-09-04 | 1999-03-11 | Biozone Laboratories, Inc. | Oral liposomal delivery system |
| PT2193809E (pt) | 1999-02-22 | 2015-08-24 | Baxter Int | Formulações de fator viii livres de albumina |
| EP2385825B1 (en) | 2008-11-07 | 2018-10-10 | University of Connecticut | Factor viii formulations |
| DE102009001334B4 (de) | 2009-03-04 | 2017-02-23 | Stefan Brosig | Einfache magensaftresistente Verkapselung, z.B. von Ingwer und anderen empfindlichen Stoffen |
| CN109316599A (zh) * | 2018-08-24 | 2019-02-12 | 上海交通大学医学院附属瑞金医院 | 一种抑肽酶或其突变体、衍生物、类似物或其组成片段的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2221122A1 (en) * | 1971-10-12 | 1974-10-11 | Bayer Ag | Encapsulation of chemical substances - in liposomes for medicinal use |
| WO1980001456A1 (en) * | 1979-01-19 | 1980-07-24 | H Hemker | Pharmaceutical composition and process for the preparation thereof |
-
1980
- 1980-10-17 JP JP55144508A patent/JPS5770814A/ja active Granted
-
1981
- 1981-10-06 GB GB8130122A patent/GB2085729B/en not_active Expired
- 1981-10-16 FR FR8119522A patent/FR2492260A1/fr active Granted
- 1981-10-16 ES ES506320A patent/ES506320A0/es active Granted
- 1981-10-16 DE DE19813141223 patent/DE3141223A1/de not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2221122A1 (en) * | 1971-10-12 | 1974-10-11 | Bayer Ag | Encapsulation of chemical substances - in liposomes for medicinal use |
| WO1980001456A1 (en) * | 1979-01-19 | 1980-07-24 | H Hemker | Pharmaceutical composition and process for the preparation thereof |
Non-Patent Citations (2)
| Title |
|---|
| BIOLOGICAL ABSTRACTS, volume 68, no. 2, 1979 (PHILADELPHIA, PENNSYLVANIA, US) & Thromb Haemostasis 40(2) 316-325, I.I. SUSSMAN et al. "Dissociation of factor VIII in the presence of proteolytic inhibitors", pages 316-325 * |
| BIOLOGICAL ABSTRACTS, volume 70, no. 8, 1980, abrégé 52897, (PHILADELPHIA, PENNSYLVANIA, US) & Anaesthesist, 29(5): 266-276, 1980, H. HARKE et al. "Aprotinin-acid citrate dextrose-blood: 1. Experimental studies on the effect of aprotinin on the plasmatic and thrombocytic coagulation", pages 266-276 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03366B2 (enrdf_load_stackoverflow) | 1991-01-07 |
| ES8306323A1 (es) | 1983-05-16 |
| GB2085729B (en) | 1984-04-18 |
| GB2085729A (en) | 1982-05-06 |
| JPS5770814A (en) | 1982-05-01 |
| ES506320A0 (es) | 1983-05-16 |
| DE3141223A1 (de) | 1982-06-24 |
| FR2492260B1 (enrdf_load_stackoverflow) | 1984-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2492260A1 (fr) | Composition pharmaceutique pour l'administration orale contenant le facteur de coagulation viii | |
| US4348384A (en) | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX | |
| WO2019236525A1 (en) | Silk-based product formulations and methods of use | |
| US5128148A (en) | Process for the production of dried earthworm powder and antihyperlipemic, antidiabetic, antihypertensive and antihypotensive preparations containing dried earthworm powder as active ingredient | |
| EP0214055A1 (fr) | Nouveaux surfactants artificiels, leur préparation et les compositions pharmaceutiques qui les contiennent | |
| WO2002003960A1 (fr) | Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs | |
| WO1996021462A1 (fr) | Compositions pharmaceutiques comprenant une superoxyde dismutase | |
| FR2577136A1 (fr) | Preparations pharmaceutiques a activite analgesique comportant des sels de diclofenac et de codeine, ainsi que leur fabrication et leur utilisation | |
| JPH09511216A (ja) | ユニラメラリポソーム性のアラキドン酸代謝物剤を用いる治療の方法 | |
| EP3313414A1 (fr) | Kit destiné au traitement du sepsis et/ou de toute hyper-inflammation généralisée (sirs) ou cellulaire dommageable | |
| EP1487466B1 (fr) | Utilisation de lactobacillus farciminis pour la prevention ou le traitement de pathologies digestives | |
| FR2646775A1 (fr) | Utilisation du caseinoglycopeptide k, notamment de lait de vache, pour la fabrication d'une composition, notamment d'un medicament, pour la prevention et le traitement des thromboses | |
| CA2251009C (fr) | Medicament optimisant la viscosite des mucus et stimulant le fonctionnement de l'intestin | |
| EP0682873B1 (fr) | Hydrolysat de protéines d'animaux marins, procédé d'obtention et applications | |
| EP1633392B1 (fr) | Vecteur pour administration par voie orale | |
| JPH02215723A (ja) | 血圧調節剤 | |
| FR2686251A1 (fr) | Composition pour la cicatrisation d'une plaie. | |
| GB2394416A (en) | Targeted delivery of microbially encapsulated drugs | |
| FR2630008A1 (fr) | Poudre de vers de terre sechee utile comme medicament et procede pour sa preparation | |
| EP1433500B1 (en) | Blood fluidity-improving health foods | |
| JP2889491B2 (ja) | 血圧降下剤 | |
| FR2622800A1 (fr) | Procede de preparation d'un produit de lutte contre des affections virales en particulier des affections virales cutaneo-muqueuses,compositions pharmaceutiques et medicaments obtenus a partir de ce procede | |
| JP4473968B2 (ja) | 血球流動性改善剤 | |
| JPH03851B2 (enrdf_load_stackoverflow) | ||
| CN117982536A (zh) | 富勒烯结构在治疗肠道屏障功能损伤方面的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |